ArticleJournal of neurology2026
Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionSerum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) may synergistically enhance early risk stratification of multiple sclerosis (MS) diagnosis after clinically isolated syndromes (CIS). We investigated the prognostic value of combined NfL and GFAP for McDonald 2024 MS diagnosis after CIS and associations with key genetic and environmental risk factors.
methodsCIS participants, within six months after symptom onset, were included in a prospective cohort. We measured baseline serum NfL and GFAP levels and calculated z-scores. We evaluated weighted genetic risk scores for MS susceptibility, HLA-DRB1*15:01 risk and measured Anti-Epstein Barr virus Nuclear Antigen-1 (anti-EBNA1) immunoglobulin G (IgG) antibodies. Associations with MS diagnosis were evaluated using Cox proportional hazards models and time-dependent receiver operating characteristic (ROC) analyses.
resultsDuring follow-up, 162/221 CIS participants were diagnosed with McDonald 2024 MS. Separately, high NfL and GFAP associated with earlier MS diagnoses (hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.12-1.66, p = 0.002, HR 1.12, 95% CI 1.02-1.42, p = 0.01, respectively). In combined models, only NfL remained independently predictive (HR 1.30, 95% CI 1.02-1.60, p = 0.01). Time-dependent ROC analyses showed similar results for NfL alone and combined with GFAP. HLA-DRB1*15:01-risk, but not GFAP or anti-EBNA1 IgG, improved predictive value.
conclusionOur study found that serum NfL outperformed GFAP in predicting early MS diagnoses after CIS. Baseline NfL, together with HLA-DRB1*15:01 status, provides robust early risk stratification for MS after CIS, whereas GFAP and anti-EBNA1 titres add limited prognostic value. Additional immunological and imaging markers are essential to further refine predictive models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.